Recombinant Lactococcus Lactis Expressing M1-HA2 Fusion Protein Provides Protective Mucosal Immunity Against H9N2 Avian Influenza Virus in Chickens
Open Access
- 24 March 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 7, 153
- https://doi.org/10.3389/fvets.2020.00153
Abstract
H9N2 subtype low pathogenicity avian influenza virus (LPAIV) is distributed worldwide and causes enormous economic losses in the poultry industry. Despite immunization of almost all chickens with inactivated vaccines, the disease still remains widespread. We speculated that improving mucosal or cellular immune responses could contribute to improved control of H9N2 viruses. In this study, we constructed a novel Lactococcus lactis (L. lactis) strain expressing a recombinant fusion protein consisting of the M1 and HA2 proteins derived from an antigenically conserved endemic H9N2 virus strain. The M1-HA2 fusion protein was cloned downstream of a gene encoding a secretory peptide, and we subsequently confirmed that the fusion protein was secreted from L. lactis by Western blotting. We assessed the immunogenicity and protective effects of this recombinant L. lactis strain. Eighty 1-day-old chickens were divided into four groups, and the experimental groups were orally vaccinated twice with the recombinant L. lactis strain. Fecal and intestinal samples, sera, and bronchoalveolar lavage fluid were collected at 7, 14, and 21 days post-vaccination (dpv). Chickens vaccinated with the recombinant L. lactis strain showed significantly increased levels of serum antibodies, T cell-mediated immune responses, and mucosal secretory IgA (SIgA). Following challenge with H9N2 virus at 21 dpv, chickens vaccinated with the recombinant L. lactis strain showed decreased weight loss, lower viral titers in the lung, and reduced lung pathological damage. In summary, our results demonstrated that a recombinant L. lactis strain expressing an H9N2 M1-HA2 fusion protein could induce protective mucosal and systemic immunity. This oral vaccine is H9N2 virus-specific and represents a significant design improvement compared with previous studies. Our study provides a theoretical basis for improving mucosal immune responses to prevent and control H9N2 virus infection.Keywords
Funding Information
- National Natural Science Foundation of China (31702254)
This publication has 37 references indexed in Scilit:
- Hemagglutinin Stalk-Based Universal Vaccine Constructs Protect against Group 2 Influenza A VirusesJournal of Virology, 2013
- Novel Reassortant Highly Pathogenic H5N2 Avian Influenza Viruses in Poultry in ChinaPLOS ONE, 2012
- Correlation between Composition of the Bacterial Community and Concentration of Volatile Fatty Acids in the Rumen during the Transition Period and Ketosis in Dairy CowsApplied and Environmental Microbiology, 2012
- Immunogenicity of Recombinant Classic Swine Fever Virus CD8+T Lymphocyte Epitope and Porcine Parvovirus VP2 Antigen Coexpressed by Lactobacillus casei in Swine via Oral VaccinationClinical and Vaccine Immunology, 2011
- Oral immunization with live Lactococcus lactis expressing rotavirus VP8* subunit induces specific immune response in miceJournal of Virological Methods, 2011
- Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1Clinical Infectious Diseases, 2011
- Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccinationProceedings of the National Academy of Sciences of the United States of America, 2007
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001
- Influenza Virus Matrix Protein Is the Major Driving Force in Virus BuddingJournal of Virology, 2000
- New strategies for using mucosal vaccination to achieve more effective immunizationVaccine, 1994